Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering
Ligand Partner Viking Therapeutics Announces Pricing of Initial Public Offering
Ligand to Participate in Two Upcoming Investor Conferences
Ligand to Report First Quarter Results on May 11th
Ligand Names Melanie J. Herman Interim Chief Financial Officer
Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting
Ligand to Present at the 27th Annual Roth Conference on March 9th
Ligand Reports Fourth Quarter and Full Year 2014 Financial Results
Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade®
Ligand Signs License Agreement with Sermonix for Lasofoxifene
Ligand Promotes Matthew W. Foehr to President
Ligand to Present at BIO CEO and RBC Capital Markets Global Healthcare Conferences in February
Ligand to Report Fourth Quarter Results on February 9th
